Comprehensive M&A data with integrated detailed company information

Roche has acquired Stratos Genomics
Posted on Friday, 22 May 2020 09:19
Roche has picked up Statos Genomics, an early-stage sequencing technology company, to advance the development of its own nanopore sequencer.

Terms of the deal, including the price, were not disclosed.

The acquisition provides Roche with access to Stratos Genomics’ unique chemistry.

Once developed, the buyer’s nanopore sequencer will utilise a novel approach that combines electronic and biological components to order DNA for fast, flexible and cost-effective clinical diagnostic testing.

Stratos Genomics will continue to operate in Seattle, Washington.

Thomas Schinecker, chief executive of Roche Diagnostics, said: “Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles.

“These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients”

Roche is a global leader in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

The group claims to be the largest biotechnology company with medicines in oncology, immunology, infectious diseases, and the central nervous system.

Headquartered in Switzerland, Roche is active in over 100 countries and in 2019 employed around 98,000 people worldwide.

Last year, the business invested CHF 11.70 billion (EUR 12.09 billion) in research and development and posted sales of CHF 61.50 billion during the same timeframe.

According to Zephyr, the M&A database published by Bureau van Dijk, there have been 288 deals targeting Western European scientific research and development services providers announced worldwide in 2020 to date.

AstraZeneca sold certain assets to Athans Pharma for USD 390.00 million in the largest of these.

UK-based Clarivate Analytics, Italy’s MolMed and Germany’s BioNTech, among others, have also been targeted in 2020 to date.

© Zephus Ltd